Data-driven investigator
& site selection
The first intelligence platform built specifically for oncology First-in-Human trials. Identify optimal principal investigators and clinical sites using evidence from PubMed, ClinicalTrials.gov, and major conference proceedings.
The Challenge
FIH site selection relies on incomplete data
Biotech sponsors spend 3–6 months on site identification using fragmented sources and personal networks. Existing enterprise tools are not designed for Phase I.
Fragmented Intelligence
Site selection data is scattered across PubMed, ClinicalTrials.gov, conference abstracts, and institutional knowledge. No single source provides a unified FIH-specific view.
Availability Blind Spots
A principal investigator with 53 FIH publications may be managing 32 concurrent trials. Publication prestige does not equal capacity for your study.
Prohibitive Pricing
Enterprise intelligence platforms (Citeline, Veeva) cost $50K–$500K annually. Pre-Series B biotechs are excluded from data-driven site selection.
Our Solution
From query to actionable intelligence
Define Parameters
Specify cancer type, mechanism of action, modality, and target geography.
NSCLC · KRAS G12D · Small molecule · US/EU
Algorithmic Matching
FIH-PRS™ scores each investigator across four evidence-based dimensions with dynamic specialty alignment.
Publication 40% · Trials 35% · Broad 15% · Alignment 10%
Actionable Output
Receive ranked investigators with availability metrics, site performance data, and collaboration network analysis.
PI Ranking · Site Ranking · Network Map · PDF Export
FIH-PRS™ Scoring Methodology
Live Data
Real rankings from verified sources
Preview our investigator and site intelligence derived from public clinical data.
Top 10 Investigators
View all →Top 10 Trial Sites
View all →Key Insight: Availability-Adjusted Rankings
David Hong (#2 by raw PRS) currently manages 32 concurrent recruiting trials — adjusted ranking drops to #10. Jordi Rodon (#8 raw) rises to #1 with only 3 recruiting trials. Publication prestige and investigator availability are frequently inversely correlated.
Validation
Backtested against real sponsor decisions
Rankings validated against 20 actual FIH trial site selections from 2024–2026.
Validation Cases
| Trial | Sponsor | Sites | Matched | Hit Rate | Top 10 |
|---|---|---|---|---|---|
| ATX-295 (KIF18A inhibitor) | Accent Therapeutics | 5 | 5 | 100% | 1 |
| VVD-133214 (covalent inhibitor) | Vividion Therapeutics | 25 | 11 | 44% | 5 |
| FOG-001 (β-catenin) | Parabilis Medicines | 23 | 7 | 30% | 4 |
| ADCE-D01 (sarcoma ADC) | Adcendo ApS | 8 | 3 | 38% | 2 |
Market Landscape
The FIH oncology market is growing rapidly
Annual FIH Oncology Trial Initiations
Competitive Positioning
| Platform | Annual Cost | FIH-Specific | Startup-Accessible |
|---|---|---|---|
| Citeline Trialtrove+ | $50K–200K/yr | No | No |
| Veeva Link | $100K–500K/yr | No | No |
| GlobalData | $30K–150K/yr | No | No |
| Expertscape | Free / Low | No | Yes |
| TriNetX | $50K+/yr | No | No |
| FIH Scout | $6K–60K/yr | Yes | Yes |
Pricing
Transparent, scalable pricing
One effective site selection decision justifies the annual investment.
Starter
For pre-IND biotech evaluating feasibility
- 5 PI/Site queries per month
- Top 20 PI + Top 10 Site results
- Cancer type + mechanism matching
- CSV export
Professional
For biotech advancing to site identification
- Unlimited queries
- Availability-adjusted rankings
- PI co-authorship network maps
- PDF briefing reports
- Specialty alignment scoring
- Conference data integration
Enterprise
For CROs and Series B+ organizations
- All Professional features
- REST API access
- Multi-user seats (5–10)
- Custom ranking models
- Quarterly landscape reports
- Dedicated success manager
Also available: FIH Annual Report 2026 — comprehensive landscape analysis, $2,000–$5,000.
Replace intuition with evidence
Join biotech sponsors and CROs using FIH Scout to identify optimal investigators and sites for first-in-human oncology trials.